Matteo Trucco

Dr. Matteo Trucco


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2024 in Cancer
Verified
Journal Article
Open access
AGAjay Gupta
Ajay Gupta
MDMatthew S. Dietz
Matthew S. Dietz
RRRichard f. Riedel
Richard f. Riedel
ADAditi Dhir
Aditi Dhir
SBScott C. Borinstein
Scott C. Borinstein
MTMatteo Trucco
Matteo Trucco
Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in children, adolescents, and young adults. Debate and controversy remain in the management of relapsed/refractory ES (RR‐ES). The authors leveraged the expertise assembled by the National Ewing Sarcoma Tumor Board, a multidisciplinary virtual tumor board that meets monthly to discuss challenging cases of ES. In this review, they focus on select topics that apply to the management of patients with RR‐ES. The specific topics covered include the initial approach of such patients and discussion of the goals of care, the role of molecular testing, chemotherapy regimens and novel agents to consider, the role of maintenance therapy, and the use of high‐dose chemotherapy with autologous stem cell rescue. The data referenced are often limited to subgroup analyses and/or compiled from multiple sources. Although not intended to replace the clinical judgement of treating physicians, these guidelines are intended to support clinicians and provide some clarity and recommendations for the management of patients with RR‐ES.Plain Language Summary: Ewing sarcoma (ES) is a bone and soft tissue cancer that most often occurs in teenagers and young adults. This article uses the experience of the National Ewing Sarcoma Tumor Board, a multi‐institution, multidisciplinary virtual tumor board that meets monthly to discuss challenging cases of ES and to address questions related to the treatment of patients with relapsed ES. Although not intended to replace the clinical judgement of treating physicians and limited by available data, these consensus recommendations will support clinicians who treat patients with this challenging malignancy, made even more difficult when it recurs.

3 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ADAditi Dhir
Aditi Dhir
MHMasanori Hayashi
Masanori Hayashi
ABAvery Bodlak
Avery Bodlak
JOJavier Oesterheld
Javier Oesterheld
DLDavid Loeb
David Loeb
LWLars Wagner
Lars Wagner
Purpose: The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease. Patients and Methods: A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response. Results: Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression. Conclusions: Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.

31 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JMJonathan Metts
Jonathan Metts
TRThomas Russell
Thomas Russell
DRDamon Reed
Damon Reed
MTMatteo Trucco
Matteo Trucco
Metastatic Ewing sarcoma has dismal long-term survival despite multiple attempts to intensify standard therapy through the addition of new agents to the existing chemotherapy backbone. Here, based on the application of evolutionary dynamics to pediatric sarcoma, we propose an alternative treatment strategy that varies exposure to agents and dosing intensities, termed sequential second-strike therapy (SSST). We announce an upcoming clinical trial to apply these principles to patients with widely metastatic Ewing sarcoma, those with metastatic disease beyond the lungs.

6 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PAPeter Anderson
Peter Anderson
ZTZheng Jin Tu
Zheng Jin Tu
SKScott Ethan Kilpatrick
Scott Ethan Kilpatrick
MTMatteo Trucco
Matteo Trucco
RHRabi Hanna
Rabi Hanna
TCTimothy A. Chan
Timothy A. Chan
(1) Background: EWS fusion genes are associated with Ewing sarcoma and other Ewing family tumors including desmoplastic small round tumor, DSRCT. We utilize a clinical genomics workflow to reveal real-world frequencies of EWS fusion events, cataloging events that are similar, or divergent at the EWS breakpoint. (2) Methods: EWS fusion events from our next-generation sequencing panel (NGS) samples were first sorted by breakpoint or fusion junctions to map out the frequency of breakpoints. Fusion results were illustrated as in-frame fusion peptides involving EWS and a partner gene. (3) Results: From 2471 patient pool samples for fusion analysis at the Cleveland Clinic Molecular Pathology Laboratory, we identified 182 fusion samples evolved with the EWS gene. They are clustered in several breakpoints: chr22:29683123 (65.9%), and chr22:29688595 (2.7%). About 3/4 of Ewing sarcoma and DSRCT tumors have an identical EWS breakpoint motif at Exon 7 (SQQSSSYGQQ-) fused to a specific part of FLI1 (NPSYDSVRRG or-SSLLAYNTSS), ERG (NLPYEPPRRS), FEV (NPVGDGLFKD) or WT1 (SEKPYQCDFK). Our method also worked with Caris transcriptome data, too. Our primary clinical utility is to use this information to identify neoantigens for therapeutic purposes. (4) Conclusions and future perspectives: our method allows interpretation of what peptides result from the in-frame translation of EWS fusion junctions. These sequences, coupled with HLA-peptide binding data, are used to identify potential sequences of cancer-specific immunogenic peptides for Ewing sarcoma or DSRCT patients. This information may also be useful for immune monitoring (e.g., circulating T-cells with fusion-peptide specificity) to detect vaccine candidates, responses, or residual disease.

18 April 2025 in Cancer
Verified
Journal Article
Open access
CSChirag Shah
Chirag Shah
SCShauna R. Campbell
Shauna R. Campbell
EMErin Murphy
Erin Murphy
SBSteve Braunstein
Steve Braunstein
MDMatthew S. Dietz
Matthew S. Dietz
MTMatteo Trucco
Matteo Trucco
Limited randomized or prospective data are available to guide local/metastasis directed therapy (LMDT) in relapsed/recurrent Ewing sarcoma (RR‐ES), resulting in uncertainty regarding best clinical practice for these patients. This report reviews the available literature on LMDT approaches and provides consensus recommendations regarding therapeutic decision making, timing, and indications for the use of LMDT in the management of RR‐ES. LMDT should be considered on a case‐by‐case basis to assess appropriateness, optimal timing/modality, palliative versus curative intent, and its role in relation to chemotherapy. One commonly used LMDT is radiotherapy (RT), which can be delivered through standard, hypofractionated, or stereotactic techniques based on factors including prior RT, tumor size, and/or location. Chemotherapy can be combined with RT, although prospective data are limited in the relapse setting. Surgery for LMDT not only addresses the tumor but also provides tissue for analysis, though the potential surgical morbidity based on location, extent of resection, and recovery complications should be considered. Interventional radiology approaches also can procure tumor tissue while delivering LMDT; there are several different procedures available based on the location, size, and extent of disease. Finally, a combination of LMDT approaches can be used for patients with RR‐ES. Decisions regarding the management of RR‐ES should involve a multidisciplinary team and factor in the burden of disease, progression‐free interval, life expectancy, toxicity profiles of LMDT, and quality of life. In such patients, informed and shared decision making with patients and their families is paramount.

20 February 2026 in Cancer
Verified
Journal Article
Open access
MDMatthew S. Dietz
Matthew S. Dietz
LDLara E. Davis
Lara E. Davis
PPPinki K. Prasad
Pinki K. Prasad
SCShauna R. Campbell
Shauna R. Campbell
JRJohn D. Reith
John D. Reith
MTMatteo Trucco
Matteo Trucco
Gnathic osteosarcoma (OS), which includes mandibular and maxillary jaw OSs, account for 6%–9% of OS. Single‐institutional and multi‐institutional retrospective studies, as well as population‐level databases, suggest that clinical differences exist among gnathic OS and OS of other sides, including other craniofacial OS. To date, no specific prospective studies of gnathic OS have been reported, and aspects of clinical management are controversial. Some elements of care are aligned with extragnathic OS, e.g., margin negative (R0) surgery, whereas others, such as chemotherapy and radiation, are not clearly defined. The authors reviewed the available literature for the diagnosis, treatment, and supportive/survivorship care patients with gnathic OS and offer consensus statements for the comprehensive management of this rare disease.